Xiaohongshu (小红书) Employees Are About to Get a Pay Raise Again

What happened

It has been reported that Xiaohongshu (小红书) is set to raise the equity grant price for employees to $30 per share, while keeping the exercise price unchanged at $2 — a paper gain of $28 per share. Reportedly this would be the fourth upward adjustment since March 2025; in a little over a year the internal grant price has climbed from $13.5 to $30, more than doubling. Employees on Chinese social platforms have celebrated and compared notes: some call swapping bonuses for options “the best financial decision of my life,” while others joke they could have skipped a year of stock trading.

That spike follows a bruising earlier stretch. In 2021 Xiaohongshu set grant prices near $10 after a high-profile financing round, only to see IPO plans stall and valuation dip — and a 2023 buyback at $8 left some option holders underwater. The 2025 rebound has been dramatic: successive rounds of higher grant benchmarks, escalating secondary-market valuations and much more generous buyback prices have let many early holders turn paper losses into sizable gains. At the same time, the company tightened vesting to a 15/25/25/35 schedule, effectively requiring new hires to stay three years to realize most upside.

Why it matters — valuation, IPO signaling and geopolitics

The broader story is about corporate signalling ahead of a potential IPO. Xiaohongshu’s internal grant moves implicitly lift its own valuation baseline; it has been reported that secondary-market quotes and private fund filings put the company well above prior levels, with some reports of secondary trades in 2025 valuing the firm substantially higher than in 2024. The user and revenue tailwinds are real: the platform’s monthly active users reportedly topped 350 million in 2025, advertising and ecommerce improvements drove strong top-line recovery, and TikTok’s regulatory troubles in the U.S. helped funnel overseas users to Chinese alternatives. But IPO timing remains sensitive — past plans were paused amid geopolitical and data-regulation concerns — and dependencies on advertising revenue and the community–commerce balance remain structural risks investors will watch.

So who wins? Early employees and patient option holders are seeing results; investors and executives hope the option-and-buyback choreography steadies staff and sets a cleaner path to listing. But the ultimate payday still hinges on one event: a public market exit. Until that bell rings, the new grant price is both encouragement and reminder — the company is valuing itself much higher, and it expects employees to believe it can deliver.